Select ongoing clinical trials with novel combinations
Agent . | Combination . | Phase . | Line of therapy . | Identifier . |
---|---|---|---|---|
Polatuzumab | Rituximab and lenalidomide | 1 | Relapsed | NCT02600897 |
Polatuzumab | Obinutuzumab, rituximab, venetoclax | 1 | Relapsed | NCT02611323 |
Polatuzumab | R-EPOCH | 1 | Frontline | NCT04231877 |
Polatuzumab | ± RGemOx | 3 | Relapsed | NCT04182204 |
Polatuzumab | + R-CHOP vs + R-CHP | 3 | Frontline | NCT04332822 |
Venetoclax | Obinutuzumab, lenalidomide, ibrutinib, prednisone | 1 | Relapsed | NCT03223610 |
Venetoclax | Rituximab and ibrutinib | 1 | Relapsed | NCT03136497 |
Venetoclax | Obinutuzumab and lenalidomide | 1 | Relapsed | NCT02992522 |
Venetoclax | Obinutuzumab | 2 | Relapsed | NCT02987400 |
Venetoclax | Rituximab and bortezomib | 2 | Relapsed | NCT02987400 |
Venetoclax | Rituximab and idasanutlin | 1/2 | Relapsed | NCT03135262 |
Venetoclax | RICE | 1/2 | Relapsed | NCT03064867 |
Selinexor | RICE | 1 | Relapsed | NCT02471911 |
Selinexor | RGDP or RDHAOx | 1b | Relapsed | NCT02741388 |
Selinexor | Ibrutinib | 1 | Relapsed | NCT02303392 |
Selinexor | Venetoclax | 1 | Relapsed | NCT03955783 |
Selinexor | R-CHOP | 1b | Frontline | NCT031478850 |
Agent . | Combination . | Phase . | Line of therapy . | Identifier . |
---|---|---|---|---|
Polatuzumab | Rituximab and lenalidomide | 1 | Relapsed | NCT02600897 |
Polatuzumab | Obinutuzumab, rituximab, venetoclax | 1 | Relapsed | NCT02611323 |
Polatuzumab | R-EPOCH | 1 | Frontline | NCT04231877 |
Polatuzumab | ± RGemOx | 3 | Relapsed | NCT04182204 |
Polatuzumab | + R-CHOP vs + R-CHP | 3 | Frontline | NCT04332822 |
Venetoclax | Obinutuzumab, lenalidomide, ibrutinib, prednisone | 1 | Relapsed | NCT03223610 |
Venetoclax | Rituximab and ibrutinib | 1 | Relapsed | NCT03136497 |
Venetoclax | Obinutuzumab and lenalidomide | 1 | Relapsed | NCT02992522 |
Venetoclax | Obinutuzumab | 2 | Relapsed | NCT02987400 |
Venetoclax | Rituximab and bortezomib | 2 | Relapsed | NCT02987400 |
Venetoclax | Rituximab and idasanutlin | 1/2 | Relapsed | NCT03135262 |
Venetoclax | RICE | 1/2 | Relapsed | NCT03064867 |
Selinexor | RICE | 1 | Relapsed | NCT02471911 |
Selinexor | RGDP or RDHAOx | 1b | Relapsed | NCT02741388 |
Selinexor | Ibrutinib | 1 | Relapsed | NCT02303392 |
Selinexor | Venetoclax | 1 | Relapsed | NCT03955783 |
Selinexor | R-CHOP | 1b | Frontline | NCT031478850 |
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHP, rituximab, cyclophosphamide, doxorubicin, and prednisone; RDHAOx, rituximab dexamethasone, cytarabine, and oxaliplatin; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; RGDP, rituximab, gemcitabine, dexamethasone, and cisplatin; RGemOx, rituximab, gemcitabine, and oxaliplatin; RICE, rituximab, ifosfamide, etoposide, and carboplatin.